Report Warns of US Drug Shortages from China Dependency
America's life-saving medicines hang by a precarious thread tied to Chinese factories, warns a new report in The National Interest. The blood thinner Heparin exemplifies the ticking time bomb: 70%...
America's life-saving medicines hang by a precarious thread tied to Chinese factories, warns a new report in The National Interest. The blood thinner Heparin exemplifies the ticking time bomb: 70% sourced from China, with US plants fully subsumed by Beijing-backed entities. Indigenous commercial production? Extinct. The 2008 Heparin horror—149 US deaths from poisoned imports affecting 11 countries—traced to Changzhou, yet Chinese denial blocked FDA probes, leaving justice elusive. Post-tragedy inaction has only worsened matters. US exits from manufacturing shrink options, fortifying China's API fortress. Rhodium Group's data reveals Beijing's 15th Plan accelerating supply chain conquests, from 192 to 315 dominant products. Biomanufacturing is pegged for breakthrough wins, mirroring coercive tactics in rare earths that jacked up prices worldwide. A supply cutoff—be it from defects or disputes—threatens dialysis patients foremost. The government's August 2025 SAPIR reserve targets six-month API buffers for key drugs, prioritizing homegrown efforts. However, flagship efforts like Flow-Barda cater to synthetic drugs, not Heparin's biological origins from porcine intestines. This report sounds a clarion call: Diversify now or face medicine rationing amid US-China strains. Rebuilding sovereignty in pharma supply demands bold investment and policy shifts to avert disaster.